相关实验视频
Updated: Jun 23, 2025

12:24
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
Published on: June 3, 2014
12.3K
八因子抑制剂绕过活动作为心脏外科手术中凝血病的第一线治疗
Hyungjoo Kim1, Frank Manetta1, Alan Hartman1
1Division of Cardiovascular and Thoracic Surgery, North Shore University Hospital, Northwell, New Hyde Park, NY.
Journal of cardiothoracic and vascular anesthesia
|June 18, 2024
概括
在心脏外科手术后凝血病的治疗中,八因子抑制剂绕过活性 (FEIBA) 可能比新鲜冷血 (FFP) 更有效. 使用FEIBA与更少的血液产品输血和更低的再接收率有关.
科学领域:
- 心血管外科心血管外科
- 血液学 血液学 血液学
- 麻醉学 麻醉学
背景情况:
- 手术后凝血病是心脏手术后的一个常见并发症.
- 新鲜冷血 (FFP) 是一种标准治疗方法,但其疗效可能有限.
研究的目的:
- 为了比较FEIBA和FFP在心脏手术后治疗凝血病的有效性.
- 评估对血液产品输血需求和患者结果的影响.
主要方法:
- 在一个单一的第三级医院进行了回顾性,倾向匹配的研究.
- 包括接受非冠状动脉心脏手术并进行心肺旁路 (2015-2023) 的患者.
- 在接受手术内FFP或FEIBA的患者之间比较结果.
主要成果:
- FEIBA 组需要更少的红细胞,血小板和冷流体输血.
- FEIBA与更短的输管时间和减少ICU停留时间有关.
- 在FEIBA组中观察到较低的30天再入院率,而血栓性并发症没有差异.
结论:
- 与FFP相比,FEIBA可能是心肺后旁路凝血病的更有效的第一线治疗方法.
- FEIBA在减少血液产品的使用和再接收方面显示出好处.
- 需要进一步的研究来支持FEIBA在这个患者群体中的常规使用.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
517
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
517
Extrinsic and Intrinsic Pathways of Hemostasis
7.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.1K
Coagulation
6.1K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.1K
Clot Retraction and Fibrinolysis
5.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.4K

